Abstract
Purpose Cervical cancer is the leading cause of cancer-associated mortalities in female worldwide. DNA methylation have been demonstrated to have a regulatory role in the progression and could be novel biomarkers to predict the recurrence of the disease.
Methods DNA methylation and RNA expression data of cervical cancer were downloaded from TCGA. DMGs and DEGs were screened and extracted by correlation analysis. The SVM-based recurrence prediction model was established using the selected DMGs. Cox regression analysis and ROC analysis were used as self-evaluations. The GEO database was applied for external validation. Functional enrichment was determined by GO and KEGG analysis.
Results The eight-DNA methylation signature could identify patients with a high risk of recurrence (AUC=0.833). The SVM score was an independent risk factor for recurrence (HR = 0.418; 95% CI: 0.26-0.67, p-value <0.05). The independent GEO database further supported the result.
Conclusion The predictive function of the 8-DNA methylation signature for recurrence of cervical cancer was revealed in this study, which may help identify high-risk patients of recurrence and benefit the clinical treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Not applicable.
